COVID VACCINE RESEARCH - DATA NOTES

Last Updated: 11 December 2020

Data and Insights Attribution: Duke Global Health Innovation Center

For Media Inquiries: Contact Jessica Harris at j.harris@duke.edu or call +1 919 668 7923

Website: https://launchandscalefaster.org/covid-19

Data Sources

1. Country population and economic status figures from World Bank
3. COVID-19 burden source: Coronavirus Pandemic Data Explorer - Our World in Data

*Source data for each deal available upon request. All deal data is from public sources at this time.

Data Notes and Frequently Asked Questions

1. **Confirmed doses** are deals that have been signed and finalized. **Potential doses** include both deals that are under negotiation (not yet final) and also options for additional doses as part of existing confirmed deals.
2. A vaccine dose is considered as one vaccine / one shot. The country coverage calculations take into consideration that some vaccines are two doses and some are one dose.
3. **Total Confirmed Doses by Country and Vaccine Candidate** table – the unknown fields represent deals under negotiation as well as confirmed deals with unknown amount.
4. Vaccine labeled as “COVAX Vaccines” is an unspecified vaccine candidate. At the time of this update, Covax has purchased 200m doses from the Serum Institute of India, which will likely be Oxford/AZ or Novavax.
5. **India Deals**: we are basing our data for India on the Serum Institute of India’s stated commitment that half of the Covid-19 vaccines they manufacture will stay in India to serve the domestic market. They currently have a contract with Novavax to produce 2b doses, so 1b of those will be reserved for India. Similarly, they have a contract to produce 1b doses for AstraZeneca, so 500m of those doses will be reserved for India.
6. **China and Russia**: We are tracking advance market purchases made by countries and reported publicly. Although Russia and China are manufacturing and exporting their own vaccines,
have not seen publicly announced purchases of vaccine candidates from either country for their domestic use, hence the reason their supply is not included in our data.

7. **EU and Latin America**: We have labeled EU as a high income region and Latin America as an upper middle income region given that the regions can be largely represented by the aforementioned income categories.

8. **Individual EU country deals**: To our understanding at the time of this update, individual countries in the EU are reporting the doses that they have been allocated from the larger EU agreement deals. These deals / doses are not being reported separately in our data for this reason until we are notified or find data that states otherwise. [Italy example](#).

9. **“Latin America without Brazil” – AstraZeneca deal**: This is a deal made by the Carlos Slim Foundation to provide 150m doses to countries in Latin America (exact countries not yet specified), with the exception of Brazil (Brazil has made a separate deal with AstraZeneca). Beyond this specific deal, Latin American countries have also made separate deals with AstraZeneca (Ecuador, Chile, Argentina, Panama, and Mexico).